Related Experiment Video
Updated: Feb 6, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
Haemolytic uremic syndrome surveillance in children less than 15 years in Belgium, 2009-2015
S Jacquinet1, K De Rauw2, D Pierard2
1Service of Epidemiology of Infectious Diseases, Department of Public Health and Surveillance, Sciensano, Brussels, Belgium.
Insights
Belgium
Area of Science:
- Pediatric infectious diseases
- Epidemiology
- Microbiology
Background:
- Haemolytic Uremic Syndrome (HUS) is a severe complication of Shiga toxin-producing Escherichia coli (STEC) infections.
- Pediatric HUS surveillance in Belgium is managed by the Pedisurv network.
- This study analyzes HUS surveillance data from 2009 to 2015.
Purpose of the Study:
- To report the main findings of pediatric HUS surveillance in Belgium.
- To describe the annual incidence of HUS in children under 15 years.
- To assess the prevalence of STEC in HUS cases.
Main Methods:
- Clinical, microbiological, and epidemiological data were collected via questionnaires for HUS cases < 15 years.
- National hospital discharge data (ICD-9 code 283.11) were used to calculate HUS incidence.
- Data from the Pedisurv network and hospital records were analyzed.
Main Results:
- 110 HUS cases were reported between 2009-2015, with a mean annual notification rate of 0.8/100,000 children < 15 years.
- STEC was confirmed in 35.4% of cases, predominantly STEC O157.
- Mean annual incidence was 3.2/100,000 children < 15 years, and 4.5/100,000 for children < 5 years.
Conclusions:
- Belgium exhibits a high incidence of pediatric HUS compared to other European nations.
- The Belgian surveillance system is comprehensive for monitoring pathogenic STEC strains.
- Enhanced sample submission to the National Reference Centre is crucial for outbreak detection.
Background:
The Haemolytic Uremic Syndrome (HUS) is the most severe manifestation of infection with Shiga toxin-producing Escherichia coli (STEC). In Belgium, the surveillance of paediatric HUS cases is conducted by a sentinel surveillance network of paediatricians called Pedisurv. In this article, we present the main findings of this surveillance from 2009 to 2015 and we describe an annual incidence of HUS.
Methods:
For each case of HUS < 15 years notified by the paediatricians, clinical, microbiological and epidemiological data were collected by a questionnaire. National hospital discharge data with ICD-9 code 283.11 were used to calculate the incidence of HUS in children < 15 years.
Results:
From 2009 to 2015, 110 cases were notified to the Pedisurv network with a mean annual notification rate of 0.8/100,000 in children < 15 years. Death occurred in 2.5% of all patients and the median number of days of hospitalization was 10 days. One third (35.4%) of the HUS cases were confirmed positive STEC, with a majority of STEC O157. The mean annual incidence based on the hospital discharge data was 3.2/100,000 in children < 15 years and 4.5/100,000 in children < 5 years.
Conclusion:
The incidence of paediatric HUS in Belgium is high compared to other European countries. Its surveillance in Belgium is quite comprehensive and, although less effective than monitoring all STEC infections to detect the emergence of outbreaks, is important to better monitor circulation of the most pathogenic STEC strains. In this context, efforts are still needed to send samples and STEC strains from HUS cases to the National Reference Centre.
Related Concept Videos
Other Nuclides: 31P, 19F, 15N NMR
While fluorine-19 and phosphorous-31 have high natural abundances (100%) and positive gyromagnetic ratios, nitrogen-15 has a low natural abundance and a negative gyromagnetic ratio. However, nitrogen-15 is still preferred over nitrogen-14 (which has a...
Principles of Disease Surveillance
Immune Surveillance by NK Cells and Phagocytes
Natural Killer Cells: The Fast Responders
NK cells are large granular lymphocytes found in the blood and lymphatic system. These...
Drug Dosing: Infants and Children
Nephrotic Syndrome I : Introduction
Acute Coronary Syndrome I: Introduction

